SkinBioTherapeutics plc
Notice of General Meeting
6 January 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") gives notice of a General Meeting on Monday 30 January 2023 at 9:00 am.
Following the Company's 2022 Annual General Meeting ("AGM"), which was held on 29 December 2022, at which time it was not possible to lay before shareholders the Company's 2022 Annual Report, a General Meeting is now being held to receive and adopt the Annual Report and Accounts, to re-appoint the auditors and to refresh the authority of the Directors to allot shares in line with the Company's enlarged share capital. The meeting will be held at The Clarion Hotel, Witney Way, Boldon, NE35 9PE on Monday 30 January 2023 at 9:00am.
The notice sent to shareholders sets out the resolutions to be proposed, together with general notes for shareholders who wish to give proxy voting instructions.
The Company's audited report and accounts for the year ended 30 June 2022, including all notes to the financial statements ("the Annual Report") was published, made available online and distributed to Shareholders on 23 December 2022.
Full details of the circular/Notice of General Meeting and associated documents are available on the Company's website.
There will be no presentations or Q&A session held as part of this meeting.
-Ends-
For more information, please contact:
| SkinBioTherapeutics plc | Tel: +44 (0) 191 495 7325 |
| Cenkos Securities Plc (Nominated Adviser & Broker) | Tel: +44 (0) 20 7397 8900 |
| Instinctif Partners (financial press) | Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics@instinctif.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
